Skip to main content

Table 1 Basic characteristics of 23 patients with primary hepatobiliary mucoepidermoid carcinoma, including in the liver, gallbladder and biliary tract, reported in the literature

From: Whole-exome sequencing reveals the etiology of the rare primary hepatic mucoepidermoid carcinoma

Case

Year

Area

Age (year)

Gender

Location

Metastasis

Size (cm)

Hepatitis

AFP ng/ml

CA199 u/ml

CEA ng/ml

Treatment

OS (day)

Reference

1

1971

Argentina

44

M

RL

Non

15

Np

Np

Np

Np

S

45

 

2

1980

Hong Kong

65

M

RL

Y

8

Np

Np

Np

Np

Con

14

 

3

 

Hong Kong

63

F

LL

Y

6

Np

Np

Np

Np

Con

16

 

4

1982

Hong Kong

44

F

LL

Non

12

HBV

Np

Np

Np

S + C

180

49

5

 

Hong Kong

66

M

BD

Y

4

Non

Np

Np

Np

PTCD+S

7

 

6

 

Hong Kong

62

M

BD

Non

1.5

Non

Np

Np

Np

S

300+

 

7

1984

Japan

78

M

LL

Y

11

Np

12.5

Np

1300

C

90

42

8

1986

Krean

35

M

LL

Non

18

Np

< 5

Np

Np

Con

14

 

9

1986

Australia

59

F

RL

Y

18

Np

Np

Np

Np

S

14

 

10

1987

Japan

46

F

LL

Non

3

Np

20

Np

Np

S

330

30

11

1992

Italy

66

F

LL

Y

9.5

Non

< 5

500

< 2

S

180

41

12

1994

Krean

68

M

LL

Non

10

Np

Np

Np

Np

TACE+C

1095

 

13

2000

Thailand

64

M

LL

Y

5

Np

Np

Np

Np

Con

210

 

14

2003

Krean

52

M

LL

Y

7

Np

< 5

400

Np

S

180

28

15

2004

Krean

69

F

RL

Y

16

Non

< 5

240

Np

S

120

 

16

2008

Japan

81

F

RL

Y

10

Non

< 5

14,893

Np

C

117

 

17

2011

Krean

70

M

BD

Y

8

HCV

< 5

349

Np

R + C

106

 

18

2012

Japan

68

M

BD

Y

5

Non

Np

50.8

Np

S + R + C

90+

29

19

2013

America

83

F

BD

Y

2

Np

Np

940

10

S + C

390

7

20

2014

China (mainland)

60

F

LL

Y

8.5

Non

< 5

50

Np

S + R

180

 

21

2019

India

50

M

GB

Y

8

Non

< 5

652

77

S

180

1

22

2019

Japan

79

F

RL

Y

4

Non

< 5

415

146

S + R + C

3650+

6

23

2020

China (mainland)

60

M

LL

Non

13

Non

< 5

151

10

S

90

present

  1. Abbreviations: Non Not have, Np Not provided, RL Right liver, LL Left liver, BD Bile duct, GB Gallbladder, HCC Hepatocellular carcinoma, CC Cholangiocarcinoma, ASC Adenosquamous carcinoma, GBC Gallbladder carcinoma, S Surgery, R: Radiotherapy, C Chemotherapy, Con Conservative, TACE Transcatheter arterial chemoembolization, PTCD Percutaneous transhepatic cholangial drainage, OS Overall survival